News

Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX: IDT) announces the final completion of the staged divestment of its CMAX clinical trial business to Japanese integrated healthcare company I’rom Group Co., Ltd (I’rom). IDT confirmsreceipt of $6,159,892 in cash for IDT’sremaining 39% stake in the CMAX business.  The final consideration payment increased from…

IDT Australia has today launched a newly responsive website created for use across mobile, tablet and desktop technologies. Retaining a quick “go-to” breakout investor section, the new site uses banner imagery and video to better showcase IDT’s award-winning API and ready for market manufacturing capabilities. “The IDT business continues to evolve, and today we offer…

The Managing Director of IDT, Dr Paul MacLeman has resigned from the position, to advance new business initiatives and to pursue further non‐executive board roles. His resignation as CEO will take effect from 31st August 2017. Dr MacLeman will resign from the Board as at close of business today. The Chairman, Mr Graeme Kaufman, thanked…

Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX: IDT) announces the retirement of our founder, Dr Graeme Blackman AO, from the Board.  Dr Blackman will remain an advisor to the Company.

Australian pharmaceutical manufacturing and drug development company IDT Australia Limited has received a Victorian Manufacturing Hall of Fame award in the High Growth Sector of Medical Technologies and Pharmaceuticals. The award recognises outstanding achievements by Victorian businesses which uphold a high standard of excellence in Victorian manufacturing. IDT’s Boronia based facility specialises in the manufacturing…